Skip to content

Clinical trials

Phase 1/2 Lymphoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma Phase: Phase 1/2 Clear all

340 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20014
20029
200314
20045
200512
200610
200711
200817
200910
20109
20116
201211
201314
201416
201516
201618
201717
201813
201911
202012
202115
202217
202313
202411
202514
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed144
Terminated61
Unknown status48
Recruiting43
Withdrawn21
Active, not recruiting17
Not yet recruiting4
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center19
National Cancer Institute (NCI)12
Memorial Sloan Kettering Cancer Center11
Incyte Corporation6
Masonic Cancer Center, University of Minnesota6
Northwestern University6
Chinese PLA General Hospital5
Fred Hutchinson Cancer Center5
Southwest Hospital, China5
Pfizer4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma340
Leukemia100
Lymphoma, Non-Hodgkin87
Lymphoma, Large B-Cell, Diffuse78
Lymphoma, Follicular69
Lymphoma, Mantle-Cell64
Leukemia, Lymphocytic, Chronic, B-Cell61
Hodgkin Disease51
Recurrence50
Burkitt Lymphoma48

Trials

Showing 76 to 100 of 340. Each trial links to its page on Pharma Observatory.

240 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.